澤璟製藥(688266.SH):2021年度預虧3.72億元-4.55億元
格隆匯1月28日丨澤璟製藥(688266.SH)公佈2021年年度業績預虧公吿,公司預計2021年度歸屬於上市公司股東的淨虧損為3.72億元-4.55億;預計2021年度扣除非經常性損益後歸屬於上市公司股東的淨虧損為4.11億元-5.09億元。
本期業績變化的主要原因系:
1、2021年6月,公司首個1類新藥甲苯磺酸多納非尼片(規格0.1g)獲批上市銷售,報吿期內產生藥品銷售收入,而上年度營業收入僅為在研產品對外授權許可收入、少量中間體銷售及技術服務收入。因此,本報吿期營業收入同比增長幅度較大。
2、報吿期內,公司處於藥品上市商業化前期拓展階段,需投入較多的前期市場拓展和學術推廣活動費用;同時,公司的新藥研發管線進一步豐富,研發項目持續推進,多個創新藥物處於關鍵臨牀試驗階段,研發支出進一步增加,公司預計2021年度研發費用約47192.13萬元到53216.66萬元,比上年同期增長15772.30萬元到21796.83萬元,同比增長50.20%到69.37%。因此,公司2021年度淨利潤仍然為負,扣除非經常性損益前後相比上年同期虧損均有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.